Shareholders Approve New Equity Plans Authorizing Over 12 Million Additional Shares
Summary
Myriad Genetics shareholders approved new equity incentive and employee stock purchase plans, authorizing the issuance of over 12.4 million additional shares, representing a potential dilution of approximately 13.2%.
Key Events
-
New Equity Incentive Plan Approved
Shareholders approved the 2026 Employee, Director and Consultant Equity Incentive Plan, authorizing the issuance of 8,463,567 shares, with a maximum potential of 8,659,575 shares.
-
Employee Stock Purchase Plan Share Increase
An amendment to the 2012 Employee Stock Purchase Plan was approved, increasing the number of shares authorized for issuance by an additional 4,000,000 shares.
-
Significant Potential Dilution
The combined authorization of new shares for both plans totals 12,463,567 shares, representing a potential dilution of approximately 13.2% based on the 94,443,029 shares outstanding as of April 8, 2026.
Analysis
Shareholders approved two new equity plans, significantly increasing the number of shares authorized for issuance. This includes an additional 4 million shares for the Employee Stock Purchase Plan and over 8.4 million shares for a new Equity Incentive Plan. This authorization represents a potential dilution of approximately 13.2% to existing shareholders, which is a substantial increase in the potential share count. This comes after the company recently reported a wider net loss for Q1 2026, making the potential dilution a key concern for investors.
At the time of this filing, MYGN was trading at $4.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $443M. The 52-week trading range was $3.53 to $8.59. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.